At Lipidica, we are committed to transforming the landscape of cancer detection to enhance early diagnosis. 

Our mission is clear: to conduct a rigorous clinical performance study according to IVDR (In Vitro Diagnostic Medical Device Regulation) and in close collaboration with clinicians, targeting individuals with hereditary/familial risk factors and validate the clinical efficacy of our LDPC lipidomic test, a breakthrough innovation in the early detection of pancreatic cancer. We are dedicated to advancing healthcare by providing clinicians with a powerful tool to identify this deadly disease at its earliest, most treatable stages.

Lipidica, a.s. was established in 2022 as a spin-off company of the University of Pardubice and the investment partner FONS JK Group a.s., based on the technology developed by the Mass Spectrometry Group of Prof. Michal Holcapek.

Lipidica, a.s.

Org chart

Teams

Offices